PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Profound Medical Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.86−0.15 (-2.50%)
Close on Oct 19, 2026
- Market cap
- $213.01M
- P/E (TTM)
- 4.2
- Dividend yield
- –
Share price
+$0.33 (+5.97%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Profound Medical Corp. grew revenue 61.2% to $19.09M over the twelve months to Jun 30, 2026. Free cash flow was -$38.38M.
Revenue
$19.09M
+61.2% vs. a year earlier
Operating income
-$35.37M
TTM Q2 2026
Free cash flow
-$38.38M
FY2025
EPS, diluted
$1.41
+25.9% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $213.01M
- P/E ratio
- 4.2
- Price to sales
- 11.16
- Price to book
- 4.28
- Dividend yield
- –
- Free cash flow yield
- -18.02%
Fundamentals
- Revenue
- $19.09M
- Net income
- -$32.75M
- EPS, diluted
- $1.41
- Free cash flow
- -$38.38M
- Book value per share
- $1.37
- Diluted shares
- 36M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$19.09M+61.2% YoY
Gross profit
$13.70M+66.7% YoY
Operating income
-$35.37M
Net income
-$32.75M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months